A single injection of sura-vec reduced the severity of nonproliferative diabetic retinopathy for up to 2 years, according to ...
Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for ...
Breakout Momentum Plays You May Not Know About; Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet ag ...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar ...
Backed by data from the phase 3 SatraGO trials, satralizumab has the potential to offer patients a convenient, at-home treatment option.
Biomedical engineers at Duke University have used induced pluripotent stem cells (iPSCs) to grow specialized blood vessel ...
FRONT-2 enrolled treatment-naïve and recently diagnosed treatment-experienced wet AMD patients, unlike the ...
Priority review positions satralizumab as a potentially practice-shifting alternative to IV IGF-1R inhibitors, primarily differentiated by subcutaneous self-administration and at-home dosing. Two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results